Navigation Links
CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix
Date:6/22/2009

SAN DIEGO, June 22 /PRNewswire/ -- CetylMax, LLC and Flexadren, LLC, manufacturers and distributors of tablet form and topical Cetylated Fatty Acids (CFA's) products aiding in joint support and pain relief, announced today that Imagenetix (OTC Bulletin Board: IAGX), the manufacturer of Celadrin, did not prevail in its claims against CetylMax(R) and Flexadren(R), and misrepresented the nature and outcome of the Federal litigation between CetylMax(R) and Flexadren(R) and Imagenetix.

Imagenetix filed a Federal lawsuit against CetylMax(R) and Flexadren(R) on July 29, 2008 ("the Imagenetix lawsuit"), in the United States District Court for the Southern District of California. The Imagenetix lawsuit claimed that CetylMax(R) and Flexadren(R) had affronted the Lanham Act and California Business and Professions Code. CetylMax(R) and Flexadren(R) vehemently denied the Imagenetix lawsuit assertions, and immediately filed their own counterclaim lawsuit against Imagenetix ("the CetylMax/Flexadren lawsuit") in the same court.

On October 27, 2008, the parties appeared before the Honorable Judge William McCurine, Jr., for an Early Neutral Evaluation Conference (ENE). At that conference the parties mutually settled all of their respective claims, raised in both the Imagenetix lawsuit and the CetylMax/Flexadren lawsuit. The sole issue left for the Court to decide was whether any attorneys' fees should be awarded.

Following briefing by the parties' attorneys, on February 2, 2009, Judge McCurine ruled that Imagenetix was not entitled to any attorneys' fees. The Court concluded that Imagenetix had not succeeded on any of its claims against CetylMax(R) or Flexadren(R), and was thus not the prevailing party. Judge McCurine's decision cleared CetylMax(R) and Flexadren(R) of any bad faith or malice.

Roger LeFevre, Chief Executive Officer of CetylMax and Flexadren, commented, "both CetylMax(R) and Flexadren(R) have been completely exonerated of all Imagenetix's claims, and we're very happy with the Court's decision."

About Cetylated Fatty Acids or CFA's -

Cetylated Fatty Acids or CFA's are rooted in a health compound(s) derived through a process of "esterifying" fatty acids. The origin of CFA's can be traced to discoveries made and processes developed by Dr. Harry W. Diehl, Ph.D., including Cetyl Myristoleate or the cetyl ester of Myristoleic Acid. CFA's are all-natural and have been clinically demonstrated to help support, and indeed restore joint health and flexibility. CFA's are marketed under various brand names, including CetylMax(R) and Flexadren(R). There have been many studies performed on and scientific presentations made relating to CFA's. Published scholarly articles have described the systemic enhancement and lubricating properties of CFA's to cell membranes throughout the body, providing youthful cell fluidity and elasticity. Some of the benefits of CFA's include the enhancement of joint fluids that cushion bones and joints ¿ to maintain flexibility and mobility, so that an individual can move with greater ease and range-of-motion. CFA's have been proven to provide cumulative (continuous and restorative) benefits.

About CetylMax(R) and Flexadren(R) --

CetylMax(R) and Flexadren(R) product lines consist of both tablet form and topical over-the-counter (OTC) joint support supplements (also known as nutraceuticals) available directly to consumers through the Internet at www.cetylmax.com and www.flexadren.com. Both products are manufactured under FDA guidelines using the highest quality formulations of Cetylated Fatty Acids or CFA's and Glucosamine. Among other positive benefits, CetylMax(R) and Flexadren(R) aid in restoring soft tissue within and lubrication of joints throughout the body, which helps ease inflammation and the pain caused by inflammation.*

CetylMax(R) and Flexadren(R) are part of the Optimal Health Science(R) www.optimalhealthscience.com family of anti-aging products.

* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.


'/>"/>
SOURCE Optimal Health Science
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvania Department of Health Applauds New Federal Anti-Tobacco Law
2. LA County Calls for Repeal of Federal Cell Tower Health Preemption
3. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
4. BioFit Intensive Plus™ Chairs Meet Federal Standard for Continuous Intensive Use
5. Medical, Insurance, Automotive and Safety Groups Call on Congress to Make This the "Last Deadly Summer for Teens" by Swiftly Passing Federal Teen Driving Safety Bill
6. Community Businesses Impacted by Looming Cuts to Long Term Care Federal Funding
7. New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction
8. Prop. 8 Challenged in Federal Court; Ted Olson & David Boies to Argue Case
9. New report on federal family planning program
10. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
11. American Association for Homecare Supports Expanded Federal Efforts by DOJ and HHS to Combat Medicare Fraud
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
Breaking Medicine Technology: